<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214903</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG 2000_3</org_study_id>
    <nct_id>NCT00214903</nct_id>
  </id_info>
  <brief_title>European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)</brief_title>
  <official_title>European Active Surveillance Study of Women Taking HRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the active surveillance study is to compare incidence rates of serious
      adverse events in users of all types of newly prescribed oral continuous combined HRT
      products. The primary focus is the assessment of pertinent cardiovascular outcomes (such as
      venous and arterial thromboembolism) in new HRT users for up to 8.5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety of a novel drug product containing a new chemical entity should be assessed in an
      extensive post marketing safety surveillance program. It is also prudent to assess both, the
      safety outcomes that relate specifically to the targeted population, as well as those that
      could potentially be related to the special pharmacological characteristics of the novel drug
      product. Differentiating between the inherent background population risk and a potential
      incremental risk due to treatment is often challenging. Active safety surveillance using
      valid epidemiological study designs has been proven to be a pertinent and reliable method to
      approach this endeavour.

      The primary objective of the study, the European Active Surveillance Study of Women taking
      HRT (EURAS-HRT), is to compare incidence rates of serious adverse events in users of all
      types of newly prescribed oral continuous combined HRT products. This active surveillance
      study will assess pertinent cardiovascular outcomes in new HRT users over a study period of
      up to 8.5 years. Also, all other serious adverse events will be reported.

      The new drug product under surveillance in the EURAS - HRT study contains the novel synthetic
      progestagen drospirenone (DRSP) combined with estradiol.

      As estrogen/progestagen combinations increase the risk for thromboembolism, all new drug
      products that contain a novel estrogen or progestagen should be investigated for their
      influence on venous and arterial thromboembolic events rates. A large, prospective,
      controlled cohort study of OC users (EURAS OC study), which compared DRSP-containing OC users
      with other OC users, demonstrated that DRSP is not associated with an increased incidence for
      any of the above-mentioned adverse events in OC users. However, because OC users are two to
      three decades younger than the typical HRT user the results of the OC study can only
      partially be extrapolated to older age groups.

      The participating women will complete a baseline survey using a self-administered
      questionnaire to describe the baseline risk. After 6 months, 12 months, and then on an annual
      basis, they will fill out a questionnaire in which they record complaints and events during
      the use of the prescribed HRTs. All adverse outcomes (including cancer) occurring during the
      observational period will be evaluated additionally. Reported serious adverse events will be
      validated and analyzed. As study participants may switch from oral continuous combined
      products to other oral or non-oral HRT products the outcomes for these preparation are
      recorded too. However, these results represent not the scientific focus of the study.

      Based on experience obtained in previous HRT studies, complex sources of bias and confounding
      are expected. Multivariate methods will therefore be used to adjust for confounding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism)</measure>
    <time_frame>within 8.5 years</time_frame>
    <description>Venous thromboembolism (VTE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke)</measure>
    <time_frame>within 8.5 years</time_frame>
    <description>Arterial thromboembolism (ATE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30597</enrollment>
  <condition>Menopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>New users of oral continuous combined HRT containing drospirenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>New users of oral continuous combined HRT containing other progestagens</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women aged 40 or more years using HRT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women aged 40 or more years who started use of a new oral HRT at the time of
             inclusion in the study

        Exclusion Criteria:

          -  Women who do not consent to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZEG, Invalidenstrasse 115, 10115 Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>November 6, 2014</results_first_submitted>
  <results_first_submitted_qc>November 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2014</results_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Juergen Dinger, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Postmenopause</keyword>
  <keyword>HRT</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 31,321 patients were recruited for the EURAS HRT study. 724 patients were excluded due to protocol violations (e.g., patient agreed to participate but never started to use the new HRT preparation or continued to use a previously prescribed preparation).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DRSP/E2</title>
          <description>Users of oral continuous combined preparations containing 2mg DRSP and 1mg estradiol</description>
        </group>
        <group group_id="P2">
          <title>ooccHRT</title>
          <description>Users of other oral continuous combined HRT preparations containing other progestogens</description>
        </group>
        <group group_id="P3">
          <title>ooHRT</title>
          <description>Users of oral but not continuous combined HRT preparations</description>
        </group>
        <group group_id="P4">
          <title>Non-oral HRT</title>
          <description>Users of non-oral HRT preparations</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10043"/>
                <participants group_id="P2" count="13384"/>
                <participants group_id="P3" count="4113"/>
                <participants group_id="P4" count="3057"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10043"/>
                <participants group_id="P2" count="13384"/>
                <participants group_id="P3" count="4113"/>
                <participants group_id="P4" count="3057"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>At baseline, 33% of women were using DRSP/E2, 44% were using ooccHRT, 13% were using ooHRT, and 10% ‘Non-oral HRT’. These proportions only partially reflect the overall exposure in each cohort (AT population) because market authorization for DRSP/E2 was delayed by more than 1.5 years.</population>
      <group_list>
        <group group_id="B1">
          <title>DRSP/E2</title>
          <description>Users of oral continuous combined preparations containing 2mg DRSP and 1mg estradiol</description>
        </group>
        <group group_id="B2">
          <title>ooccHRT</title>
          <description>Users of other oral continuous combined HRT preparations containing other progestogens</description>
        </group>
        <group group_id="B3">
          <title>ooHRT</title>
          <description>Users of oral but not continuous combined HRT preparations</description>
        </group>
        <group group_id="B4">
          <title>Non-oral HRT</title>
          <description>Users of non-oral HRT preparations</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10043"/>
            <count group_id="B2" value="13384"/>
            <count group_id="B3" value="4113"/>
            <count group_id="B4" value="3057"/>
            <count group_id="B5" value="30597"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="6.4"/>
                    <measurement group_id="B2" value="55.1" spread="6.9"/>
                    <measurement group_id="B3" value="52.9" spread="8.3"/>
                    <measurement group_id="B4" value="56.2" spread="7.7"/>
                    <measurement group_id="B5" value="54.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10043"/>
                    <measurement group_id="B2" value="13384"/>
                    <measurement group_id="B3" value="4113"/>
                    <measurement group_id="B4" value="3057"/>
                    <measurement group_id="B5" value="30597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>This study was conducted in seven European countries: Austria, Belgium, Germany, Italy, the Netherlands, Spain, and Turkey. 23,025 participants were eligibly enrolled in Central Europe, and 7,572 participants in Southern Europe.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10043"/>
                    <measurement group_id="B2" value="13384"/>
                    <measurement group_id="B3" value="4113"/>
                    <measurement group_id="B4" value="3057"/>
                    <measurement group_id="B5" value="30597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism)</title>
        <description>Venous thromboembolism (VTE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.</description>
        <time_frame>within 8.5 years</time_frame>
        <population>The number of participants refers to the ITT study population. During the course of the study, women could for example stop hormonal treatment at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP/E2</title>
            <description>Users of oral continuous combined preparations containing 2mg DRSP and 1mg estradiol</description>
          </group>
          <group group_id="O2">
            <title>ooccHRT</title>
            <description>Users of other oral continuous combined HRT preparations containing other progestogens</description>
          </group>
          <group group_id="O3">
            <title>ooHRT</title>
            <description>Users of oral but not continuous combined HRT preparations</description>
          </group>
          <group group_id="O4">
            <title>Non-oral HRT</title>
            <description>Users of non-oral HRT preparations</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism)</title>
          <description>Venous thromboembolism (VTE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.</description>
          <population>The number of participants refers to the ITT study population. During the course of the study, women could for example stop hormonal treatment at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10043"/>
                <count group_id="O2" value="13384"/>
                <count group_id="O3" value="4113"/>
                <count group_id="O4" value="3057"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Women-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13,714"/>
                <count group_id="O2" value="31,938"/>
                <count group_id="O3" value="9,253"/>
                <count group_id="O4" value="7,785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the VTE hazard ratio for DRSP/E2 vs. ooccHRT is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on a non-inferiority test to exclude a two-fold risk of cardiovascular events in users of DRSP/E2 compared to other oral continuous combined HRT. These calculations are based on the following assumptions: 1) one-sided α 0.05; 2) power (1-β) of 0.80; 3) Estimated incidence of cardiovascular events, ATE and VTE would be at least 1.0, 0.3 and 0.2 event/100 woman-years and 4) non-inferiority limit hazard ratio of 2.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, duration of current use, family history of VTE, region, and HRT user status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke)</title>
        <description>Arterial thromboembolism (ATE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.</description>
        <time_frame>within 8.5 years</time_frame>
        <population>The number of participants refers to the ITT study population. During the course of the study, women could for example stop hormonal treatment at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP/E2</title>
            <description>Users of oral continuous combined preparations containing 2mg DRSP and 1mg estradiol</description>
          </group>
          <group group_id="O2">
            <title>ooccHRT</title>
            <description>Users of other oral continuous combined HRT preparations containing other progestogens</description>
          </group>
          <group group_id="O3">
            <title>ooHRT</title>
            <description>Users of oral but not continuous combined HRT preparations</description>
          </group>
          <group group_id="O4">
            <title>Non-oral HRT</title>
            <description>Users of non-oral HRT preparations</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke)</title>
          <description>Arterial thromboembolism (ATE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.</description>
          <population>The number of participants refers to the ITT study population. During the course of the study, women could for example stop hormonal treatment at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10043"/>
                <count group_id="O2" value="13384"/>
                <count group_id="O3" value="4113"/>
                <count group_id="O4" value="3057"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Women-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13,714"/>
                <count group_id="O2" value="31,938"/>
                <count group_id="O3" value="9,253"/>
                <count group_id="O4" value="7,785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the ATE hazard ratio for DRSP/E2 vs. ooccHRT is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on a non-inferiority test to exclude a two-fold risk of cardiovascular events in users of DRSP/E2 compared to other oral continuous combined HRT. These calculations are based on the following assumptions: 1) one-sided α 0.05; 2) power (1-β) of 0.80; 3) Estimated incidence of cardiovascular events, ATE and VTE would be at least 1.0, 0.3 and 0.2 event/100 woman-years and 4) non-inferiority limit hazard ratio of 2.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, hypertension, diabetes, family history of fatal ATE, region, and smoking.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events was collected over a time period of 8.5 years.</time_frame>
      <desc>Complete cohorts, as-treated population. All study participants were asked for adverse events at each follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>DRSP/E2</title>
          <description>Users of oral continuous combined preparations containing 2mg DRSP and 1mg estradiol</description>
        </group>
        <group group_id="E2">
          <title>ooccHRT</title>
          <description>Users of other oral continuous combined HRT preparations containing other progestogens</description>
        </group>
        <group group_id="E3">
          <title>ooHRT</title>
          <description>Users of oral but not continuous combined HRT preparations</description>
        </group>
        <group group_id="E4">
          <title>Non-oral HRT</title>
          <description>Users of non-oral HRT preparations</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="707" subjects_at_risk="10043"/>
                <counts group_id="E2" subjects_affected="1998" subjects_at_risk="13384"/>
                <counts group_id="E3" subjects_affected="576" subjects_at_risk="4113"/>
                <counts group_id="E4" subjects_affected="508" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the blood and bloodforming organs</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10043"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13384"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4113"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular system</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="135" subjects_affected="135" subjects_at_risk="10043"/>
                <counts group_id="E2" events="542" subjects_affected="542" subjects_at_risk="13384"/>
                <counts group_id="E3" events="155" subjects_affected="155" subjects_at_risk="4113"/>
                <counts group_id="E4" events="130" subjects_affected="130" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="10043"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="13384"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="4113"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine diseases</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="10043"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="13384"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="4113"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="10043"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="13384"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="4113"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive system</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="90" subjects_affected="90" subjects_at_risk="10043"/>
                <counts group_id="E2" events="237" subjects_affected="237" subjects_at_risk="13384"/>
                <counts group_id="E3" events="69" subjects_affected="69" subjects_at_risk="4113"/>
                <counts group_id="E4" events="68" subjects_affected="68" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious diseases</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="10043"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="13384"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="4113"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, accidents, etc.</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="93" subjects_affected="93" subjects_at_risk="10043"/>
                <counts group_id="E2" events="226" subjects_affected="226" subjects_at_risk="13384"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="4113"/>
                <counts group_id="E4" events="64" subjects_affected="64" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscoskeletal system &amp; connective tissue</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="117" subjects_affected="117" subjects_at_risk="10043"/>
                <counts group_id="E2" events="285" subjects_affected="285" subjects_at_risk="13384"/>
                <counts group_id="E3" events="85" subjects_affected="85" subjects_at_risk="4113"/>
                <counts group_id="E4" events="70" subjects_affected="70" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms, malignant and benign</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="10043"/>
                <counts group_id="E2" events="248" subjects_affected="248" subjects_at_risk="13384"/>
                <counts group_id="E3" events="62" subjects_affected="62" subjects_at_risk="4113"/>
                <counts group_id="E4" events="58" subjects_affected="58" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric and neurological disorders</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="10043"/>
                <counts group_id="E2" events="112" subjects_affected="112" subjects_at_risk="13384"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="4113"/>
                <counts group_id="E4" events="32" subjects_affected="32" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary system</sub_title>
                <description>This adverse event term also includes renal and urinary disorders. Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="10043"/>
                <counts group_id="E2" events="111" subjects_affected="111" subjects_at_risk="13384"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="4113"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="10043"/>
                <counts group_id="E2" events="78" subjects_affected="78" subjects_at_risk="13384"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="4113"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <description>Prespecified category; a further breakdown by sub-categories was only planned in case that the results indicated an increased risk for DRSP/E2.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10043"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="13384"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="4113"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10043"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3057"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In non-experimental studies like EURAS-HRT the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Juergen Dinger, MD, PhD</name_or_title>
      <organization>Center for Epidemiology and Health Research, Germany</organization>
      <phone>+49 (0) 30 945 101 20</phone>
      <email>dinger@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

